Efficacy Optimizing Research of Lamivudine Therapy (EXPLORE)
A Prospective, Randomised, Open-label, Multi-centre Study to Compare Three Chronic Hepatitis B (CHB) Treatment Strategies Over a 2year Period in Chinese HBeAg Positive CHB Patients
Sponsor: GlaxoSmithKline
Listed as NCT01088009, this PHASE4 trial focuses on Compensated Chronic Hepatitis B and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2010, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2023 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Mar 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Major Science and Technology Special Project of China Eleventh Five-year
- Nanfang Hospital, Southern Medical University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Foshan, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Jinan, China and 5 more locations